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A multimodality approach including operation and isolated lung perfusion 
with platinum was used in six patients with lung metastases from soft tissue 
sarcomas. Staged thoracotomies were used in two patients with bilateral 
lesions. The inclusion criteria generally applied for surgical excision were 
adopted in this study. The pulmonary artery and a portion of the left atrium 
were isolated from systemic irculation and cannulated. The cannulas were 
then connected to a perfusion circuit and normothermic isolated lung 
perfusion was done for 60 minutes. The lung was then flushed and 
metastasectomy was done. Serial blood (systemic and pulmonary), tissue 
(normal lung and tumor), and urine samples were obtained for platinum 
content measurement by flameless atomic absorption spectroscopy. Lung 
damage was assessed by light and electron microscopy examination and by 
serial respiratory tests. Isolated lung perfusion was accomplished in all 
patients without any death, operative complication, or systemic toxicity. 
After operation, interstitial and alveolar edema developed in two patients 
(48 hours after treatment), necessitating respiratory support in one case. 
Total platinum concentrations in pulmonary plasma were about 43 times 
greater than those in systemic plasma. No differences in platinum concen- 
trations between normal lung and metastatic tissue were found. Thus the 
proposed isolated lung perfusion technique is feasible and safe enough to 
be offered as a valid model to study combined chemosurgical approaches 
in the treatment of lung metastases. (J Thorac Cardiovasc Surg 1996; 
112:614-22) 
L ong-term survival has been reported in approxi- mately 20% to 30% of patients with lung metas- 
tases from soft tissue sarcomas who underwent 
pulmonary resection. TM Chemotherapy has given 
promising results, l' 5 but the overall response rate to 
systemic drug administration remains 20% to 30% 
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for doxorubicin and 20% to 50% for combination 
chemotherapy. 4-7These findings would support he 
need for a multimodality approach to the treatment 
of pulmonary metastases from soft tissue sarcomas. 
In such a combined therapeutic program, surgical 
treatment would decrease the tumor burden by 
removing the macroscopic component of the disease 
and chemotherapy would eradicate the microscopic 
loci. 3 The concept of a distant spread phase during 
which metastases would be restricted to the lung 
could make metastases from soft tissue sarcomas an 
ideal model for the application of regional chemo- 
therapy. This administration modality would in- 
crease the local biologic effect while reducing sys- 
temic toxicity. Thirty-five years ago Pierpont and 
Blades 8 and Jacobs, Flexner, and Scott 9 described 
methods for isolated single-lung perfusion in the 
dog. Subsequently, with animal models, Johnston 
and colleagues l° demonstrated that isolated lung 
perfusion is a reproducibly safe technique, causing 
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Table I. Clinical and pathologic data 
Disease-free Pulmonary 
Sarcoma histologic interval metastases 
Patient Age (yr) Sex type Sarcoma location (too) (No. and site) 
1 33 M Synovial Knee 137 6 (eR/2L) 
2 68 F Rhabdomyosarcoma Gluteus 47 2R 
3 65 F Rhabdomyosarcoma Uterus 26 3L 
4 54 F Angiosarcoma Thigh 16 14 (5R/9L) 
5 53 F Leiomyosarcoma Uterus 54 3R 
6 61 F Leiomyosarcoma Retroperitoneum 73 5L 
M, Male; R, right; L, left; F, female. 
only mild histologic changes in the treated organ. 
Two-lung perfusion has been accomplished in a 
single patient with unresectable pidermoid carci- 
noma by means of two extracorporeal circuits (for 
pulmonary and systemic circulation). 11 The tech- 
nique of isolated lung perfusion we used in the 
present study has been previously developed in our 
laboratory. 12 
Major end points of the present study were (1) to 
assess the feasibility, under routine hospital condi- 
tions, of a protocol including isolated lung perfusion 
with platinum and metastasectomy, (2) to evaluate 
the overall toxicity of the combined therapeutic 
program, and (3) to define the distribution of plat- 
inum in both normal and neoplastic tissues. A minor 
end point was the assessment of platinum pulmo- 
nary toxicity, by investigating the relevant morpho- 
functional changes. 
Methods 
To allow clear assessment of the procedure, single-drug 
therapy was used. In the present study, we used acisplatin 
dose (200 mg/m 2) similar to the highest dose used in the 
experimental model (5 mg/kg), a2 Such a drug dosage was 
selected because a 5 mg/kg dose of platinum proved to 
cause, in the pig, acute lung changes imilar to those 
induced by lower doses. The study protocol was approved 
by the Scientific Committee of the National Cancer 
Institute of Genoa. Patients with histologically confirmed 
soft tissue sarcomas who had evidence of lung metastases 
were eligible. Inclusion criteria were (1) age younger than 
70 years; (2) performance status from 0 to 1; (3) no 
demonstrable extrapulmonary metastases; (4) control of 
the primary tumor; (5) prediction of complete resectabil- 
ity of all known metastatic disease; (6) cardiac and lung 
reserve consistent with the planned operation; and (7) 
adequate hematologic, hepatic, and renal function. All 
patients were informed about the potential benefits and 
hazards of this experimental treatment and gave their 
consent. No patient was excluded on the basis of (1) the 
duration of the interval between treatment of the primary 
tumor and appearance of neoplastic deposits in the lung 
or (2) the number and size of pulmonary metastases. 
Preoperative valuation included chest roentgenogram, 
lung and cardiovascular function evaluation, arterial 
blood gas measurements, bronchoscopy, computed to- 
mography of the chest and abdomen, ultrasonography and 
computed tomography (supplemented or not by magnetic 
resonance imaging) of the primary sarcoma region, and 
bone scan. Clinical and pathologic data are reported in 
Table I. Two patients had bilateral ung metastases and 
underwent staged thoracotomies, with bilateral lung per- 
fusion and metastasis resection, at a 4-week interval. 
At the time of the operation, regional chemotherapy 
was given as the first treatment modality because blood 
supply was still not compromised by metastasectomy. A 
muscle-sparing anterolateral thoracotomy at the fifth in- 
tercostal space was used. The pulmonary artery and veins 
were exposed by incision of the pericardium. The left 
pulmonary artery was dissected free and occluded by a 
vascular clamp lateral to its origin. The right pulmonary 
artery was clamped between the ascending aorta and the 
superior vena cava. The lateral portion of the atrium was 
freed to allow use of a Satinsky clamp to occlude the atrial 
chamber draining the veins of the perfused lung. Thus the 
circulation of the lung to be perfused was completely 
isolated from the systemic circulation, except for the 
bronchial blood that flowed into the venous return. 
Polypropylene purse-string sutures were placed in the 
pulmonary artery and the superior pulmonary vein. Care 
was taken to locate the tip of the venous catheter in the 
atrial chamber and to avoid venous congestion. The 
vessels were cannulated by a 16F/18F right-angled perfu- 
sion catheter (Bard, Tewksbury, Mass.). Intravenous hep- 
arin was given (5000 units) before cannulation. The 
cannulas were then connected to the perfusion circuit. 
The circuit mainly consisted of i/e-inch polyvinylchloride 
tubing joining the venous drainage cannula to a bubble 
oxygenator (model D700S Dideco, Mirandola, Italy) con- 
nected with a heat exchanger. The bloodstream was driven 
with a roller pump from the oxygenator to the arterial 
cannula. A cardiotomy reservoir (model D742, Dideco) 
was included in the circuit just downstream of the oxygen- 
ator to make possible the washing phase of the treatment. 
Venous outflow was obtained by gravity. A bypass was 
located between the arterial and venous lines to allow 
exclusion of the patient from the extracorporeal circula- 
tion (Fig. 1). 
By selection of a temperature of 38 ° to 39 ° C on the 
heat exchanger, the lung perfusion temperature ranged 
from 37 ° to 37.5 ° C. The temperature was monitored with 
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Fig. 1. Diagram of perfusion circuit. OX, Oxygenator. 
thermoprobes positioned in the arterial and venous lines 
and in the inflow and outflow lines of the oxygenator. The 
body temperature was continuously checked with an 
esophageal probe. Though the systemic temperature was 
always unmodified, the head of the patient was wrapped 
with a refrigerated cuff, and a water-circulating mattress 
was located under the patient. 
The extracorporeal circuit was primed with polygeline 
(Haemaccel, Hoechst Ltd., Hounslow, United King- 
dom) (500 ml), acetate Ringer's solution (500 ml), 
tromethamine (250 ml), and heparin (75 mg). The lung 
perfusion flow rate was monitored with an electromag- 
netic flow probe and was maintained between 200 and 280 
ml/min to prevent he mean pulmonary artery pressure 
from exceeding 35 mm Hg, in view of findings that high 
arterial pressure values may cause significant lung dam- 
age. z° Lung perfusion was done for 60 minutes. The even 
distribution of the perfusate throughout the lung tissue 
was assessed in two patients by infusion of methylene 
blue dye, as previously describedfi The perfusate pH 
was maintained between 7.3 and 7.4 by addition of 
tromethamine. The isolated lung was not ventilated ur- 
ing perfusion, and the perfusate was oxygenated to pre- 
vent pulmonary vasoconstrictio n as a result of hypoxia. At 
the conclusion of lung perfusion, the perfusate was dis- 
carded and the circuit was washed (at the flow rate used 
during the perfusion) with 4000 ml of lactated Ringer's 
solution (containing bicarbonate and an antiproteinase) 
to remove unbound platinum. Blood gas values and the 
acid-base ratio were kept in the physiologic range. After 
the cannulas were removed, heparin was reversed with 
protamine sulfate. 
A systematic examination of the entire lung field and 
the mediastinum was then done. All palpable nodules 
were removed with the use of stapling devices. Lobectomy 
was done in one case only, with limited resections being 
the operation of choice. 
Blood samples were collected from the perfusion circuit 
and from the general circulation before, at completion of, 
and 15, 30, 45, and 60 minutes after cisplatin infusion for 
determination of hematocrit, hemoglobin, and blood gas 
values and acid-base balance. At the same observation 
times, systemic and pulmonary blood, normal ung paren- 
chyma, neoplastic tissue, and mediastinal node samples 
were obtained for platinum content measurement and 
morphologic examination. Only lung metastases smaller 
than 1 cm were used for pharmacokinetic studies because, 
in our therapeutic program, lung perfusion was applied to 
sterilize microscopic residual neoplastic loci. Systemic 
plasma platinum concentrations were also assessed 6 and 
12 hours after treatment. Overall lung function was eval- 
uated before and 10, 30, and 90 days after treatment by 
means of lung volume and airflow measurements and 
determination fpulmonary diffusing capacity and arterial 
blood gas values. Ventilation/perfusion scans were done in 
three patients 90 days after treatment. 
For plasma platinum value determination, blood sam- 
ples (3 ml) were collected in heparinized tubes and 
immediately centrifuged. Separation of ultrafilterable 
(free) platinum from total platinum in the plasma was 
done by centrifugation through anisotropic, hydrophilic 
YMT ultrafiltration (Amicon Corp., Lexington, Mass.) 
membranes (molecular weight cutoff: 30,000) in a Micro- 
partition System instrument (Amicon Corp., Lexington, 
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Mass.). Plasma and plasma ultrafiltrate were stored at 
-20 ° C until analysis. Urine samples were collected be- 
fore cisplatin administration a d then from 2-hour pools 
during a 24-hour period. The volume of urine for each 
collection period was recorded. Tissue samples were 
digested with a 4 mol/L concentration f nitric acid; after 
evaporation tonear dryness the residue was dissolved in a 
10 mmol/L concentration of itric acid. Each sample was 
compared with appropriate standards to take the matrix 
effect into account. Platinum concentrations in plasma, 
plasma ultrafiltrate (free platinum), urine, and tissues 
were determined by flameless atomic absorption spectros- 
copy according to the technique described by Pera and 
Harder, 13 with use of a Hitachi model Z-9000 polarized 
Zeeman spectrophotometer (W. Pabisch Instrument, Mi- 
lan, Italy). The accuracy of platinum determinations was 
verified by neutron activation analysis, as previously de- 
scribed. 14 
Lung specimens for morphologic evaluation of paren- 
chymal damage were obtained before drug infusion and at 
the completion of treatment. Samples were divided into 
two halves. The first half was prefixed (1 hour) in Bouin's 
solution and used for light microscopy investigations. The 
second half was fixed in 2.5% glutaraldehyde solution and 
used for scanning (SEM) and transmission electron mi- 
croscopy (TEM) examinations. 
The area under the concentration x time curve (AUC) 
from 0 to 60 minutes was estimated by the trapezoidal 
rule. The indices of platinum exposure were the observed 
plasma platinum concentrations and the AUC values. 
Repeated-measures analysis of variance was used to as- 
sess changes with ime of the investigated lung function 
parameters. 
Results 
After 60-minute lung perfusion, the volume of the 
circuit priming fluid was increased by 50% (700 ml); 
this was most likely caused by bronchial flow emp- 
tying into the pulmonary circulation. The overall 
procedure was completed in every case, and no 
complications occurred uring the operation (mean 
duration, 220 minutes). There were no intraopera- 
tive or postoperative deaths. The only postoperative 
complication (2 cases) was the development, 48 
hours after treatment, of radiologic signs of intersti- 
tial and alveolar edema, depicting the previously 
described "contusion syndrome ''15 (Fig. 2). In one 
case, prolonged (5 days) respiratory support was 
needed, whereas the other patient recovered after 2 
days of standard medical therapy. The mean hospi- 
tal stay was 11 days (range, 8 to 17 days). There was 
no late morbidity caused by the procedure. At a 
median follow-up of 13 months (range, 9 to 21 
months), four patients are alive without any evi- 
dence of disease relapse. One patient died of ex- 
trapulmonary metastases 11 months after the oper- 
ation. The remaining patient had both local and 
Fig. 2. Chest roentgenogram, 48 hours after isolated lung 
perfusion, showing conspicuous interstitial and alveolar 
edema in treated organ. 
distant disease relapse 9 months after treatment. 
Traditional chemotherapy toxicity, such as myelo- 
suppression, ausea nd vomiting, and alterations in 
creatinine, nitrogen, sodium, and potassium blood 
values, never occurred. 
Platinum concentrations in the pulmonary and 
systemic plasma are reported in Fig. 3. The AUC 
(AUC: 0 to 60 minutes) values (milligrams/milliliter 
× minute) for total platinum concentrations in 
pulmonary and systemic plasma were 12.8 (SD,* 
5.6) and 0.30 (SD, 0.2), respectively. Systemic 
plasma total platinum concentrations 6 and 12 hours 
after treatment were 0.25 /xg/ml (SD, 0.4) and 0.23 
/xg/ml (SD, 0.4), respectively. Ultrafilterable plati- 
num was never detectable in systemic plasma. These 
figures relate to the pulmonary-to-systemic cross- 
over, which was very small. The half-life for total 
and ultrafilterable platinum in pulmonary plasma 
was 1.08 hours (SD, 0.6) and 0.89 hours (SD, 0.3), 
respectively. Total platinum concentrations in the 
normal lung parenchyma nd metastatic tissue are 
illustrated in Fig. 4. At the completion of lung 
perfusion, total platinum concentration i  mediasti- 
nal lymph nodes was 2.57 /xg/gm wet weight (SD, 
1.47). The mean percentage of platinum excreted in 
the urine up to 24 hours after cisplatin administra- 
tion was 0.88% (SD, 0.30%) of the administered 
platinum dose. 
Changes of ventilatory function parameters are 
illustrated in Fig. 5. The analysis of variance showed 
*Standard deviation. 
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Fig. 3. Semilogarithmic plot of total and filterable plati- 
num (PT) concentrations versus time, in systemic and 
pulmonary plasma, during isolated lung perfusion (values 
represent means plus or minus standard eviation). 
significant differences between preoperative val- 
ues and those registered either 10 or 30 days after 
treatment (forced vital capacity [FVC]: p < 0.001; 
forced expiratory volume in 1 second [FEV1]: p < 
0.02; carbon monoxide diffusing capacity: p = 
0.02). Ventilatory parameters were functionally 
reassessed in two patients 12 months after the 
procedure and showed a further improvement 
(13% reduction of both FVC and FEV 1 with 
respect to preoperative values). Postoperative 
lung scanning showed no evidence of ventilation/ 
perfusion mismatch, although scattered efects of 
both ventilation and perfusion were seen. Histo- 
logic examination of normal lung parenchyma 
showed no damage as a result of the perfusion 
with platinum. TEM and SEM examinations evi- 
denced the integrity of the alveolar septa and 
epithelial ining. Minimal cellular changes, such 
as mild pneumocyte hypertrophy with ectasia of 
the smooth endoplasmic reticulum were seen 
(Fig. 6). 
70 
o Normal Lung 
• Metastasis 
60 
50 
' 3 ~ 15 0 60 
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Fig. 4. Platinum (PT) concentrations i  normal lung and 
neoplastic tissue during isolated lung perfusion (values 
represent means plus or minus standard eviation). 
Discussion 
The reasons that support a multimodality ap- 
proach for the treatment of lung metastases from 
soft tissue sarcomas have already been empha- 
sized. 16 The rational basis for use of regional che- 
motherapy rests on the concept hat, in the meta- 
static cascade, there is a phase during which the 
disease is limited to the lung. This concept is sup- 
ported by numerous findings: (1) the lung is the first 
district of metastatic spread in approximately 80% 
of sarcomas 4' s, 15, 17; (2) pulmonary metastases are 
the primary cause of death in patients with sarco- 
ma 3, is; (3) even after a complete resection of pul- 
monary metastases, the major recurrence site re- 
mains the lungl; and (4) many patients who die with 
pulmonary metastatic disease have no extrathoracic 
spread at autopsy. & 19 The approach of combining 
surgical excision with regional chemotherapy has 
been previously used in patients with localized mel- 
anoma of the limbs and was found to offer the best 
chance for cure. 2° The present experience shows 
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Fig. g. Changes of pulmonary function parameters before and after isolated lung perfusion. DLCO, 
diffusing capacity of carbon monoxide; Po2, oxygen tension; Pco2, carbon dioxide tension. 
that such a combined approach may also be applied 
to the lung. 
We used cisplatin, an antineoplastic agent, be- 
cause (1) the drug had been used in our previous 
experimental study, with results that suggested acute 
lung damage would be low 12 and (2) platinum 
antitumor activity has been reported for a great 
variety of tumors, with the percentage of objective 
responses in adult soft tissue sarcomas being about 
20%.7, 21 Because our previous experimental study 
suggested that the overall toxicity of the combined 
treatment was more related to the surgical trauma 
(including extracorporeal circulation) than to the 
drug dose, we planned a pilot study to investigate 
the feasibility of the procedure, instead of a phase I
trial. We believed it would have been unethical to 
apply escalating doses of cisplatin, because patients 
treated with suboptimal drug doses would still un- 
dergo the surgical trauma and this would not be 
balanced by an adequate probability of treatment 
efficacy. 
The outstanding clinical finding of this study is the 
demonstrated feasibility of a therapeutic program 
including metastasectomy and isolated lung perfu- 
sion with cisplatin. The overall procedure issafe and 
the operative risk and short- and long-term morbid- 
ity remained low. However, because interstitial and 
alveolar pulmonary edema may occur during the 
postoperative p riod, an intensive care unit must be 
available. 
Systemic side effects, both subjective and hema- 
tologic, as the result of antineoplastic drug admin- 
istration were always absent. This finding possibly 
depends on the lack of significant platinum escape 
from the perfusion circuit to the general circulation. 
If we assume that side effects consequent tocisplatin 
administration are related to the concentrations f 
filterable platinum in plasma, 22' 23 it is likely that the 
reduced systemic exposure to active platinum spe- 
cies, observed in patients undergoing lung perfusion 
with cisplatin, may account for the absence of 
systemic toxicity. 
Rather than systemic platinum toxicity, lung tol- 
erance of the drug is likely to be the limiting factor. 
No Serious acute damage to the pulmonary paren- 
chyma has morphologically been demonstrated. Ei- 
ther the epithelial alveolar lining or the capillary 
membrane was intact. This finding is in keeping with 
the experimental data obtained from our laborato- 
ry.12 However, the interval between treatment and 
lung specimen removal was too short to draw final 
conclusions. Investigations to estimate long-term 
toxicity in animal models are ongoing. Changes of 
ventilatory function parameters after treatment 
were consistent with the reduction of lung volumes 
as a result of metastasectomy. The decrease of 
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Fig. 6. TEM and SEM appearances of normal pulmonary parenchyma after 1 hou of isolated lung 
perfusion. Top left, Intact interalveolar septum with minimal pneumocyte hypertrophy (TEM, original 
magnification ×4400). Top right, Detail of interalveolar septum showing pneumocyte with mild ectasia of 
smooth endoplasmic reticulum (TEM, original magnification ×3000). Bottom left, Undamaged capillary 
wall (TEM, original magnification ×4400). Bottom right, Complete and uninjured alveolar epithelial lining 
(SEM, original magnification ×390). 
carbon monoxide iffusing capacity was also com- 
patible with lung volume reduction, although per- 
meability changes may not be excluded. Neverthe- 
less, functional changes eemed to be reversible, as 
suggested by the progressive tendency to recovery. 
Lung damage during perfusion was avoided by 
maintenance of an appropriate osmolarity of the 
perfusate, high oxygen tensions in the circuit, an 
unobstructed pulmonary venous return, and flow 
rates to prevent high pulmonary artery pressure. 
However, the individual effects of the perfusate 
composition, platinum toxicity, and pulmonary cir- 
culation patterns on lung damage are difficult to 
separate. 
According to the results of our previous experi- 
mental study, the present clinical trial confirmed 
that great pharmacokinetic advantages are attained 
with the use of the isolated lung perfusion tech- 
nique. It also demonstrated that no significant dif- 
ference in drug extraction exists between normal 
lung and neoplastic tissue. The technique we have 
applied implies a number of points that could give 
rise to criticisms. 
First, although isolated perfusion of both lungs 
has already been accomplished with use of two 
completely separate pumping circuits, 11'24 we 
adopted a lateral approach with single-lung explo- 
ration. Consequently, staged thoracotomy was re- 
quired in patients with bilateral disease. Indeed, the 
use of a median sternotomy would make the proce- 
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dure significantly harder and increase the risk of 
postoperative r spiratory impairment, because of to 
the potential of a bilateral pulmonary contusion 
syndrome. Moreover, there is no general agreement 
on the best approach for the treatment of lung 
metastases.2S, 26 Sequential operations at the time 
lesions become evident on computed tomographic 
scan have been reported to be as efficacious as early 
excision of occult tumors. 25 Residual posterior nod- 
ules have been found at a subsequent exploration in 
patients who had undergone resection through me- 
dian sternotomy. 18We can state that staged lung 
perfusion through lateral thoracotomy is a safe 
procedure and would not result in tumor unresect- 
ability at the second operation. 
Second, isolated lung perfusion is a single-course 
treatment, the effectiveness of which remains un- 
known. However, in patients already scheduled for 
metastasectomy, the procedure does not require 
extensive additional trauma and it may be followed 
by either conventional chemotherapy or different 
types of regional chemotherapy. 
Third, the criteria that identify patients who will 
benefit from isolated lung perfusion remain unset- 
tled. The prediction of a complete resection and the 
absence of disease outside the chest were the main 
criteria we adopted. Other indicators, including the 
number of metastases, the disease-free interval, and 
the tumor doubling time, were not taken into ac- 
count, because there is no unanimity on their prog- 
nostic value. 26 In the present series, two patients 
with 6 and 14 nodules, respectively, underwent lung 
perfusion, although this finding has been associated 
with an unfavorable outcomeT The first patient is 
alive without any evidence of disease relapse 10 
months after the operation, whereas the other pa- 
tient died of extrapulmonary metastases 11 months 
after treatment. 
Fourth, the use of the isolated lung perfusion 
technique assumes that pulmonary metastases are 
supplied by the pulmonary circulation and that the 
neoplastic tissue takes up antitumor drugs at a rate 
similar to that of lung tissue. The major blood 
supply to lung metastases through the pulmonary 
artery has been demonstrated by several investiga- 
tions.28, 29 Our study showed that, during perfusion, 
lung and tumor are exposed to similar concentra- 
tions of platinum, at least when the metastasis 
diameter is smaller than 1 cm. Platinum concentra- 
tions in larger metastases were not investigated, 
because they were removed uring the operation. 
Fifth, the systemic-to-pulmonary crossover of 
blood (representing the fraction of the bronchial 
flow that empties into the pulmonary circulation) 
added a dilutional volume to the pulmonary perfu- 
sion circuit, resulting in a decrease of platinum 
concentration in the perfusate greater than that 
caused by drug uptake. To avoid the progressive 
decrease of platinum concentrations in the perfus- 
ate, additional doses of the drug could be fraction- 
ally administered. This administration modality has 
already been tested in our animal model. 12 
In conclusion, this study demonstrated that nor- 
mothermic isolated perfusion of a single lung with 
platinum can be accomplished without serious sLs- 
temic toxicity or adverse clinical effects. Lung dam- 
age seems to be reversible to some degree. Because 
the perfusion system is a closed circuit, manipula- 
tions of the system conditions (hyperthermia) 3° or 
perfusate composition (tumor necrosis factor, 31 
anticancer drug association) could be done to en- 
hance the treatment effectiveness. 
The technical assistance of M. Galanti in the prepara- 
tion of this manuscript is gratefully acknowledged. 
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